Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

Krisztián Szigeti, Nikolett Hegedus, Kitti Rácz, I. Horváth, Dániel S. Veres, Dávid Szöllosi, Ildikó Futó, K. Módos, Tamás Bozó, K. Karlinger, Noémi Kovács, Z. Varga, Magor Babos, Ferenc Budán, Parasuraman Padmanabhan, Balázs Gulyás, Domokos Máthé

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm3) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

Original languageEnglish
Article number2023604
JournalContrast Media and Molecular Imaging
Volume2018
DOIs
Publication statusPublished - Apr 26 2018

Fingerprint

Thallium
Citric Acid
Nanoparticles
Single-Photon Emission-Computed Tomography
Contrast Media
Iron
Kidney
Atomic Force Microscopy
Liver
Salivary Glands
Isotopes
Intravenous Administration
ferric ferrocyanide
Lung
Injections
Brain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent. / Szigeti, Krisztián; Hegedus, Nikolett; Rácz, Kitti; Horváth, I.; Veres, Dániel S.; Szöllosi, Dávid; Futó, Ildikó; Módos, K.; Bozó, Tamás; Karlinger, K.; Kovács, Noémi; Varga, Z.; Babos, Magor; Budán, Ferenc; Padmanabhan, Parasuraman; Gulyás, Balázs; Máthé, Domokos.

In: Contrast Media and Molecular Imaging, Vol. 2018, 2023604, 26.04.2018.

Research output: Contribution to journalArticle

Szigeti, K, Hegedus, N, Rácz, K, Horváth, I, Veres, DS, Szöllosi, D, Futó, I, Módos, K, Bozó, T, Karlinger, K, Kovács, N, Varga, Z, Babos, M, Budán, F, Padmanabhan, P, Gulyás, B & Máthé, D 2018, 'Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent', Contrast Media and Molecular Imaging, vol. 2018, 2023604. https://doi.org/10.1155/2018/2023604
Szigeti, Krisztián ; Hegedus, Nikolett ; Rácz, Kitti ; Horváth, I. ; Veres, Dániel S. ; Szöllosi, Dávid ; Futó, Ildikó ; Módos, K. ; Bozó, Tamás ; Karlinger, K. ; Kovács, Noémi ; Varga, Z. ; Babos, Magor ; Budán, Ferenc ; Padmanabhan, Parasuraman ; Gulyás, Balázs ; Máthé, Domokos. / Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent. In: Contrast Media and Molecular Imaging. 2018 ; Vol. 2018.
@article{e210d695d6434ad08da15f65d675e6c2,
title = "Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent",
abstract = "Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm3) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.",
author = "Kriszti{\'a}n Szigeti and Nikolett Hegedus and Kitti R{\'a}cz and I. Horv{\'a}th and Veres, {D{\'a}niel S.} and D{\'a}vid Sz{\"o}llosi and Ildik{\'o} Fut{\'o} and K. M{\'o}dos and Tam{\'a}s Boz{\'o} and K. Karlinger and No{\'e}mi Kov{\'a}cs and Z. Varga and Magor Babos and Ferenc Bud{\'a}n and Parasuraman Padmanabhan and Bal{\'a}zs Guly{\'a}s and Domokos M{\'a}th{\'e}",
year = "2018",
month = "4",
day = "26",
doi = "10.1155/2018/2023604",
language = "English",
volume = "2018",
journal = "Contrast Media and Molecular Imaging",
issn = "1555-4309",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent

AU - Szigeti, Krisztián

AU - Hegedus, Nikolett

AU - Rácz, Kitti

AU - Horváth, I.

AU - Veres, Dániel S.

AU - Szöllosi, Dávid

AU - Futó, Ildikó

AU - Módos, K.

AU - Bozó, Tamás

AU - Karlinger, K.

AU - Kovács, Noémi

AU - Varga, Z.

AU - Babos, Magor

AU - Budán, Ferenc

AU - Padmanabhan, Parasuraman

AU - Gulyás, Balázs

AU - Máthé, Domokos

PY - 2018/4/26

Y1 - 2018/4/26

N2 - Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm3) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

AB - Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm3) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.

UR - http://www.scopus.com/inward/record.url?scp=85046630255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046630255&partnerID=8YFLogxK

U2 - 10.1155/2018/2023604

DO - 10.1155/2018/2023604

M3 - Article

C2 - 29853803

AN - SCOPUS:85046630255

VL - 2018

JO - Contrast Media and Molecular Imaging

JF - Contrast Media and Molecular Imaging

SN - 1555-4309

M1 - 2023604

ER -